The Pathology Department at Massachusetts General Hospital and Lunaphore, a Swiss life sciences company, entered a collaboration to develop an in vitro diagnostic that evaluates sensitivity of solid tumors to poly-ADP ribose polymerase inhibitors, with an initial focus on ovarian, breast, and prostate cancers.
A study led by investigators from the Mass General Cancer Center, a member of Mass General Brigham, in collaboration with researchers at the Massachusetts Institute of Technology, developed and tested an artificial intelligence tool that accurately predicted the risk of lung cancer for individuals with or without a significant smoking history.
